Related Experiment Video

Updated: Aug 15, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Treatment of hepatitis C virus in HIV patients: a review

Nickolas Kontorinis1, Kaushik Agarwal, Douglas T Dieterich

  • 1Department of Medicine, Mount Sinai Hospital, New York, NY 10029, USA. nick.kontorinis@health.wa.gov.au

AIDS (London, England)
|October 28, 2005
PubMed

Insights

HIV patients with Hepatitis C Virus (HCV) infection require careful management. Evidence-based treatment strategies, including pegylated interferon and ribavirin, are effective and safe for managing HCV in this population.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Antiviral Therapy

Background:

  • Antiretroviral therapy (ART) has improved HIV survival, but Hepatitis C Virus (HCV) coinfection is prevalent (approx. 30%).
  • HCV coinfection significantly increases liver-related mortality in HIV patients.
  • ART can exacerbate hepatotoxicity in coinfected individuals, making HCV treatment a priority.

Purpose of the Study:

  • To review and summarize current evidence-based management of anti-HCV therapy in HIV-infected patients.
  • To provide guidance on the treatment of HCV in the context of HIV infection.

Main Methods:

  • A systematic literature review was conducted.
  • Searches were performed using PubMed and Medline databases.

Main Results:

  • Screening for HCV via antibody and RNA testing is recommended for all HIV patients.
  • Treatment should be considered for coinfected patients with liver inflammation and fibrosis.
  • Pegylated interferon and ribavirin combination therapy demonstrates safety and efficacy.

Conclusions:

  • HCV treatment duration of 48 weeks is more effective for genotypes 2 and 3.
  • Clinicians must be aware of unique side effects and toxicities associated with interferon-based therapy in HIV patients.
  • HCV genotype predicts treatment response.
Abstract

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...